🚀 VC round data is live in beta, check it out!
Otsuka Holdings Valuation Multiples
Discover revenue and EBITDA valuation multiples for Otsuka Holdings and similar public comparables like Teva Pharmaceuticals, BeOne Medicines, Sandoz, Insmed and more.
Otsuka Holdings Overview
About Otsuka Holdings
Otsuka Holdings Co Ltd is a Japan-based company that operates in pharmaceuticals, nutraceuticals, and consumer products. It operates through four reportable segments: Medical-related Business, Nutraceutical-related Business, Consumer-related Business, and Other Business. The Medical Business manufactures and sells therapeutic drugs and infusions, the Nutraceutical Business produces functional foods, beverages, and nutritional supplements, the Consumer Business offers mineral water, beverages, and foods, while the Other Business provides storage services and manufactures chemicals and analytical equipment. It generates the majority of its revenue from the medical-related business segment.
Founded
2008
HQ
Employees
40.5K
Website
Sectors
Financials (LTM)
EV
$32B
Otsuka Holdings Financials
Otsuka Holdings reported last 12-month revenue of $16B and EBITDA of $4B.
In the same LTM period, Otsuka Holdings generated $11B in gross profit, $4B in EBITDA, and $2B in net income.
Revenue (LTM)
Otsuka Holdings P&L
In the most recent fiscal year, Otsuka Holdings reported revenue of $16B and EBITDA of $4B.
Otsuka Holdings expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $16B | XXX | $16B | XXX | XXX | XXX |
| Gross Profit | $11B | XXX | $11B | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | $4B | XXX | $4B | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 24% | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 15% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Otsuka Holdings Stock Performance
Otsuka Holdings has current market cap of $35B, and enterprise value of $32B.
Market Cap Evolution
Otsuka Holdings' stock price is $65.66.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $32B | $35B | -1.8% | XXX | XXX | XXX | $4.50 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOtsuka Holdings Valuation Multiples
Otsuka Holdings trades at 2.0x EV/Revenue multiple, and 9.0x EV/EBITDA.
EV / Revenue (LTM)
Otsuka Holdings Financial Valuation Multiples
As of April 14, 2026, Otsuka Holdings has market cap of $35B and EV of $32B.
Equity research analysts estimate Otsuka Holdings' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Otsuka Holdings has a P/E ratio of 15.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $35B | XXX | $35B | XXX | XXX | XXX |
| EV (current) | $32B | XXX | $32B | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 9.0x | XXX | 8.5x | XXX | XXX | XXX |
| EV/EBIT | 11.0x | XXX | 10.4x | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | 2.9x | XXX | XXX | XXX |
| P/E | 15.6x | XXX | 14.6x | XXX | XXX | XXX |
| EV/FCF | 20.9x | XXX | 19.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Otsuka Holdings Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Otsuka Holdings Margins & Growth Rates
Otsuka Holdings' revenue in the last 12 month grew by 0%.
Otsuka Holdings' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Otsuka Holdings' rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Otsuka Holdings' rule of X is 28% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Otsuka Holdings Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | (8%) | XXX | (15%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 28% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 12% | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 39% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 14% | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 50% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Otsuka Holdings Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Otsuka Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Teva Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| BeOne Medicines | XXX | XXX | XXX | XXX | XXX | XXX |
| Sandoz | XXX | XXX | XXX | XXX | XXX | XXX |
| Insmed | XXX | XXX | XXX | XXX | XXX | XXX |
| Daiichi Sankyo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Otsuka Holdings M&A Activity
Otsuka Holdings acquired XXX companies to date.
Last acquisition by Otsuka Holdings was on XXXXXXXX, XXXXX. Otsuka Holdings acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Otsuka Holdings
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOtsuka Holdings Investment Activity
Otsuka Holdings invested in XXX companies to date.
Otsuka Holdings made its latest investment on XXXXXXXX, XXXXX. Otsuka Holdings invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Otsuka Holdings
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Otsuka Holdings
| When was Otsuka Holdings founded? | Otsuka Holdings was founded in 2008. |
| Where is Otsuka Holdings headquartered? | Otsuka Holdings is headquartered in Japan. |
| How many employees does Otsuka Holdings have? | As of today, Otsuka Holdings has over 40K employees. |
| Who is the CEO of Otsuka Holdings? | Otsuka Holdings' CEO is Makoto Inoue. |
| Is Otsuka Holdings publicly listed? | Yes, Otsuka Holdings is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Otsuka Holdings? | Otsuka Holdings trades under 4578 ticker. |
| When did Otsuka Holdings go public? | Otsuka Holdings went public in 2010. |
| Who are competitors of Otsuka Holdings? | Otsuka Holdings main competitors are Teva Pharmaceuticals, BeOne Medicines, Sandoz, Insmed. |
| What is the current market cap of Otsuka Holdings? | Otsuka Holdings' current market cap is $35B. |
| What is the current revenue of Otsuka Holdings? | Otsuka Holdings' last 12 months revenue is $16B. |
| What is the current revenue growth of Otsuka Holdings? | Otsuka Holdings revenue growth (NTM/LTM) is 0%. |
| What is the current EV/Revenue multiple of Otsuka Holdings? | Current revenue multiple of Otsuka Holdings is 2.0x. |
| Is Otsuka Holdings profitable? | Yes, Otsuka Holdings is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Otsuka Holdings? | Otsuka Holdings' last 12 months EBITDA is $4B. |
| What is Otsuka Holdings' EBITDA margin? | Otsuka Holdings' last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of Otsuka Holdings? | Current EBITDA multiple of Otsuka Holdings is 9.0x. |
| What is the current FCF of Otsuka Holdings? | Otsuka Holdings' last 12 months FCF is $2B. |
| What is Otsuka Holdings' FCF margin? | Otsuka Holdings' last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Otsuka Holdings? | Current FCF multiple of Otsuka Holdings is 20.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.